ARTICLE | Clinical News
Influenza DNA vaccine: Phase I expanded
December 10, 2007 8:00 AM UTC
VICL expanded an ongoing double-blind, placebo-controlled Phase I trial to evaluate Vaxfectin-formulated DNA vaccine delivered via syringe or the Biojector 2000 jet injector system. The study already...